This one will be very interesting. This is one of few analysts who lower target drastically to $15 (Or may be 12, don't remember). Q&A should give idea about how honest analyst with his rating and how HGSI defend it (if Analyst is honest with his/her rating & ask question that really matter).
This excahnge can also serve as game changer; especially if HGSI confirms target market size is >100,000 patients in USA and confirm their confidence in achieving high penetration (>70%) with target audience in 2 years in USA. This equals to $2 billion in USA alone. If BOA analyst turns around and upgrades to BUY with target of $20 something; watch out; Shorts will scramble like wilderbeast crossing the river. Triceptorman rocket, and his 1000 aliases will be trampled alive:-)))))